Rheumatoid Arthritis: Overview
Rheumatoid arthritis is an autoimmune disease in which your immune system assaults the tissue that lines your joints. It affects both sides of your body’s joints, which distinguishes it from other types of arthritis. Some of the common areas such as knees, hands, and ankles where the disease attacks, and it usually adversely impacts the same joint on both sides of the human body. However, RA can affect other regions of the body as well, including the eyes, heart, circulatory system, and/or lungs.
A normal healthy person with a properly functioning immune system comfortably battles intruders such as viruses and germs. When a person struggles with a RA, that person’s immune system misidentifies the body’s cells as bad outsider invaders. Then it releases inflammatory chemicals to fight against such outsider invaders. Because it can swiftly deteriorate, early detection and vigorous treatment are critical. Every year, 71 persons out of 100,000 are diagnosed with RA. RA affects about 1.5 million people in the United States. Women are two to three times more likely than males to get RA. Hormones from both sexes could play a role in avoiding or initiating it.
Report Key Takeaways
Recommended Drug or Treatment for Rheumatoid Arthritis:
Analgesics are recognized as the mostly used treatment option for RA. Non-opioid analgesics are usually effective for people who experiences the mild-to-moderate RA pain. Whereas, opioids and opioid combos are more effective in treating severe pain. Side effects such as sleepiness and constipation are possible as a result of the increased effectiveness.
- Janus kinase (JAK) inhibitors
These are a newer type of disease-modifying antirheumatic drugs (DMARDs) that inhibit specific immune responses. When DMARDs and biologic DMARDs don’t work, your healthcare professional may prescribe JAK inhibitors to help prevent inflammation and stop joint deterioration.
Instead of suppressing your body’s whole immune system reaction, these new biologic DMARDs deliver a focused response to inflammation. They are an effective treatment for patients who do not react to more standard DMARDs.
Recent Developments Related to Rheumatoid Arthritis
- RiabniTM, a biosimilar to Rituxan® (rituximab), has been approved by the Food and Drug Administration (FDA) for use in individuals with moderately to severely active rheumatoid arthritis who have had an insufficient response to one or more tumour necrosis factor (TNF) antagonist treatments. Adults with non-Hodgkin lymphoma, chronic lymphocytic leukaemia, granulomatosis with polyangiitis, and microscopic polyangiitis can also take Riabni.
- A latest study published in Nature Medicine and conducted by the Queen Mary University of London that is related to the rheumatoid arthritis. As per the research study findings, the molecular profiling of joint tissue which having issues can have a significant influence impact on the treatment for patients having rheumatoid arthritis. During the study, the researchers have also found that certain types of genes linked to resistance to most available medications, which is a special condition known as refractory illness. The findings could lead to the development of advance drugs to aid these people.
Major Players Working on Rheumatoid Arthritis
As per the global rheumatoid arthritis pipeline, there are several leading companies operating in the field such as Astellas Pharma, Gilead Sciences, Baylx, Ablynx, Genor Biopharma, Amgen, Cyxone, Sanofi, Sorrento Therapeutics, R-Pharm, Oryn Therapeutics, Arthrogen, and Celltex Therapeutics.
Key Reasons to Purchase This Report
- The pipeline insight covers a competitive outlook of the industry, focusing on the latest developments, drug pipeline, and significant licensing activities.
- A coverage of modern novel therapies and emerging technologies related to therapeutics of rheumatoid arthritis.
- An in-depth overview of clinical trials that are currently under research globally as possible treatments for the rheumatoid arthritis.
